CLINICAL TRIAL

pembrolizumab for Mesothelioma

Waitlist Available · 18+ · All Sexes · Commack, NY

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

See full description

About the trial for Mesothelioma

Eligible Conditions
Pleural Diseases · Metastases · Breast Cancer · Malignant Pleural Disease · Mesothelioma · Lung Cancers

Treatment Groups

This trial involves 3 different treatments. Pembrolizumab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Experimental Group 1
pembrolizumab
DRUG
Experimental Group 2
iCasp9M28z T cell infusions
GENETIC
Experimental Group 3
cyclophosphamide
DRUG
+
iCasp9M28z T cell infusions
GENETIC

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Pembrolizumab
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Mesothelioma or one of the other 5 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The text discusses people with non-small cell lung cancer that has spread to the pleura (the membrane that lines the lungs and chest cavity) show original
Patients with pleural effusion who require management will be given a pleural catheter show original
Patients with cancer that has spread to the pleura and who have been treated with at least one prior treatment regimen are eligible for the study show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether pembrolizumab will improve 2 primary outcomes and 1 secondary outcome in patients with Mesothelioma. Measurement will happen over the course of at 12 weeks following the first dose of pembrolizumab.

clinical benefit rate (phase II)
AT 12 WEEKS FOLLOWING THE FIRST DOSE OF PEMBROLIZUMAB
rate will be defined as the proportion of patients with a response of complete response (CR), partial response (PR), and stable disease (SD) as measured by mRECIST criteria.
Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP) (Phase I)
60 DAYS (+/-5 DAYS) AFTER TREATMENT
Mesothelin is an immunogenic cell surface antigen, that is expressed at high levels in MPD and mesothelioma pleural fluid will be drained from the chest by thoracentesis or through a pleural catheter and will be preserved for analysis .
Composite measure of severity and number of adverse events (AEs); changes in (clinical laboratory test findings (hematologic and chemistry); and physical examination. (Phase I)
1 YEAR
All AEs and laboratory toxicities will be graded using version 4 of the CTCAE.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can mesothelioma be cured?

Symptoms can be eliminated in a significant number of malignant mesotheliomas provided that patients are treated as early as possible and with the utmost efficiency and speed. However, curative measures do not allow for cure of this malignant tumour.

Anonymous Patient Answer

How many people get mesothelioma a year in the United States?

Approximately 5-6,000 people are diagnosed with mesothelioma a year in the United States. This makes it a rare disease that causes around 2,800 deaths a year in the US. meso<nowiki>'</nowiki>sothelioma does not only kill people by causing suffocation but can also kill through its toxic side effects.\nquestion: How many people get [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) a year in the United States?\nanswer: In 2013, approximately 1,430,500 women were diagnosed with breast cancer in the United States. This makes it one of the most common cancer among women in the United States.

Anonymous Patient Answer

What causes mesothelioma?

Mesothelioma can occur at multiple sites in the body, and it can occur at all levels of the respiratory tract. The most common occurrence is in the thoracic cavity, due to exposure to asbestos. Mesothelioma can spread from the lung to other organs and is often accompanied by malignant pleural mesothelioma. Mesothelioma is a rare cancer, but it has a high prevalence in certain parts of the world, and it is diagnosed in many people. Most patients have the disease for five to 10 years before the diagnosis is made.

Anonymous Patient Answer

What are common treatments for mesothelioma?

Treatment is dependent on the stage of disease, symptoms, and prognosis. A prospective clinical trial would reveal the best treatment to be used and the best stage of disease to avoid. mesothelioma.

Anonymous Patient Answer

What are the signs of mesothelioma?

The signs of mesothelioma include weight loss, fatigue, loss of appetite etc. The cancer may be mistaken in the medical history for benign disease, thus leading to further delay in diagnosis and treatment.

Anonymous Patient Answer

What is mesothelioma?

A mesothelium is a thin waxy membranous covering that envelops the visceral and/or parietal peritoneum that protects its function. Mesothelium forms the lining that covers the inner (and some of the outer) surfaces of the cavities in the human body, particularly blood vessels. Mesothelioma is most often caused by asbestos exposure. It can also occur from exposure to asbestos-containing products. Mesothelioma's appearance depends on the location in the body that is affected. Mesotheliomas most often occur in the abdomen (or abdomen part of the thorax), thorax, and on the neck (or neck part of the thorax).

Anonymous Patient Answer

What is the primary cause of mesothelioma?

Data from a recent study shows that mesothelioma can occur independently in both genders and in all segments of the population, in all age groups and the elderly also get mesothelioma. The overall survival of patients with mesothelioma is very poor, especially in females. Data from a recent study shows that the incidence and outcome of mesothelioma cases were different in different countries and in different areas of the country as well, which would be due to the environmental influence of asbestos dusts.

Anonymous Patient Answer

What is the latest research for mesothelioma?

It is important that people get tested for cancer, even if they think it is an 'old disease' like mesothelioma. In addition to screening, it is also recommended to be checked over time, with regular examination, X-ray analysis and medical imaging. For women, breast screenings are advised more frequently, particularly during pregnancy. And for people of all ages, cancer screening programs can be valuable for assessing risk factors and for detecting early signs and symptoms of cancer.

Anonymous Patient Answer

What does pembrolizumab usually treat?

Pembrolizumab treatment usually results in improvement in symptoms, including the sensation of weight loss. However, most patients develop progressive disease, and experience a decrease in time to progression and progression-free survival. Patients should understand that despite a change in the pattern of symptoms to a more favorable one, there is no change in the rate of progression or overall survival. These data suggest that treatment with pembrolizumab should be discontinued or discontinued early in patients with progression in order to maximize survival.

Anonymous Patient Answer

What is the survival rate for mesothelioma?

Survival rates are highly variable between patients with different stages and different types of the disease. Typically, early stage is associated with better survival. However, some patients with more advanced disease can have survival rates of 50% to 100%. Patients must understand survival rates vary widely depending on how they are diagnosed, when they seek treatment, and how well they’re treated once they arrive at the hospital. Although lung and heart are the most common sites for mesothelioma, a small number of cases come from a number of other organs. The most common site is the diaphragm; a small number come from the liver, ovaries, and even the adrenal glands.

Anonymous Patient Answer

Have there been any new discoveries for treating mesothelioma?

In a recent study, findings showed that many studies used insufficient and non-quality research methodology methods. We also suggest the need for more studies, and more scientific research, on the treatments of mesothelioma.

Anonymous Patient Answer

What are the chances of developing mesothelioma?

It is important for physicians to be vigilant around diagnosis and treatment of mesothelioma. In certain populations, however, the risk of developing mesothelioma is increased. These individuals are candidates to be examined for symptoms of asbestos exposure, and/or examination of the pleura, if possible.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Mesothelioma by sharing your contact details with the study coordinator.